Introduction
============

An increase in the prevalence of dementia has become a serious social problem due to an aging society. Dementia is currently the main cause of dependency in older individuals and a major public health concern affecting approximately 36 million people worldwide. The prevalence of dementia rapidly increases from approximately 2-3% among individuals aged 70-75 years to 20-25% among those aged 85 years or more [@B1], and the number affected by dementia is expected to double between 2020 and 2040 [@B2].

Anxiolytics are frequently used for the treatment of mood or anxiety disorders and depression in the elderly in many countries, and benzodiazepines are commonly prescribed for this purpose [@B3], [@B4]. However, it is inconclusive as to whether their long-term use is effective and safe. Among the elderly, user prevalence as high as 25% has been reported [@B5]. Recently, some studies suggested that the use of benzodiazepines in the elderly is associated with an increased risk of incident cognitive decline or dementia [@B6]-[@B9]. Zhong et al. reported in a meta-analysis of nested case-control or prospective cohort studies that long-term benzodiazepine users have an increased risk of dementia compared with never users [@B10]. Billioti de Gage et al. systematically reviewed published observational studies assessing the relationship between benzodiazepine use and dementia and concluded that exposure to benzodiazepines was associated with a 1.5- to 2-fold increased risk of dementia [@B11].

On the other hand, some studies suggested that the observed association between benzodiazepine use and dementia might be due to confounding by indication and reverse causation. Certainly, anxiety can be a prodromal symptom of dementia and is the main indication for prescribing benzodiazepines [@B12]. Therefore, this association might be considered an early marker of a condition associated with an increased risk of dementia rather than a cause of the dementia itself. Overall, the possibility of an increased risk of dementia is still a matter of debate.

Recently, data mining of medical databases including spontaneous adverse drug reaction databases, claims databases, and prescription databases was reported [@B13], [@B14]. Some different methodologies and algorithms have been applied to identify safety signals within these medical databases. The aim of this study was to examine the association between benzodiazepine use and dementia using different methodologies, algorithms, and databases.

Methods
=======

Spontaneous adverse drug reaction databases
-------------------------------------------

### Data sources

The US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) and the Canada Vigilance Adverse Reaction Online Database are computerized information databases designed to support post-marketing safety surveillance programs for all approved drugs and therapeutic biological products. The FAERS contains all reports of adverse events reported spontaneously by health care professionals, manufacturers, and consumers worldwide. The Canada Vigilance Adverse Reaction Online Database contains all domestic reports of adverse events reported spontaneously by health care professionals, manufacturers, and consumers. The FAERS consists of seven datasets that include patient demographic and administrative information (file descriptor DEMO), drug and biologic information (DRUG), adverse events (REAC), patient outcomes (OUTC), report sources (RPSR), start and end dates of drug therapy (THER), and indications for use/diagnosis (INDI). A unique number for identifying a FAERS report allows all of the information from different files to be linked. Raw data from the FAERS database can be downloaded freely from the FDA website (<http://www.fda.gov/Drugs/InformationOnDrugs/ucm135151.htm>). Data from the first quarter of 2004 through the end of 2013 were included in this study. A total of 4,866,160 reports were obtained. Reports with a common CASE number were identified as duplicate reports, which we excluded from the analyses. Finally, a total of 65,146,507 drug-reaction pairs were identified from 4,081,582 reports.

The Canada Vigilance Adverse Reaction Online Database consists of 11 data files that include information on reports and patients (Reports.txt), drug names and their codes (Drug_Product.txt), the active ingredients associated with all drugs (Drug_Product_Ingredients.txt), the reaction terms associated with the report (Reactions.txt), outcome presentation text associated with the outcome code (Outcome_LX.txt), gender presentation text associated with the gender code (Gender_LX.txt), report type presentation text associated with the report type code (Report_Type_LX.txt), report seriousness presentation text associated with the report seriousness code (Seriousness_LX.txt), report source presentation text associated with the report source code (Source_LX.txt), linked/duplicate reports presentation text associated with the code (Report_Links_LX.txt), drugs associated with specific reports (Report_Drug.txt), and indications associated with specific reports (Report_Drug_Indication.txt). Raw data from the Canada Vigilance Adverse Reaction Online Database can be downloaded freely from the Health Canada website (<http://www.hc-sc.gc.ca/dhp-mps/medeff/databasdon/index-eng.php>). Data from the first quarter of 1965 through the end of 2013 were included in this study. A total of 4,019,652 drug-reaction pairs were identified from 381,822 reports.

The Medical Dictionary for Regulatory Activities (MedDRAR version 17.0) preferred terms (PTs) were used to classify the adverse events.

Identification of benzodiazepine anxiolytic drugs
-------------------------------------------------

Benzodiazepines with the World Health Organization Anatomical and Therapeutic Chemical code of N05C were defined as benzodiazepine anxiolytic drugs in this study (Table [1](#T1){ref-type="table"}). A drug name archive that included the names of all preparations, generic names, and drug synonyms marketed worldwide was created using the Martindale website ([https://www.medicinescomplete.com/mc/login.htm](http://www.medicinescomplete.com/mc/login.htm)). Benzodiazepine anxiolytic drugs were identified by linking this archive with the FAERS database and the Canada Vigilance Adverse Reaction Online Database (Table [1](#T1){ref-type="table"}). All records including benzodiazepine anxiolytic drugs were selected, and the relevant reactions were then identified.

Definition of adverse events
----------------------------

Adverse events in the FAERS and the Canada Vigilance Adverse Reaction Online Database were coded using the MedDRA® PTs, which are categorized by defined medical condition or area of interest. Using the Standardized MedDRA® Queries, we identified 82 PTs in the category of dementia.

Statistical analysis
--------------------

The reporting odds ratio (ROR) [@B15] and the information component (IC) [@B16] were used to detect spontaneous report signals. These signal scores were calculated using a case/non-case method [@B17], [@B18]. Cases are the reports involving the event of interest (i.e., dementia) and the non-cases all other reports. ROR and IC are widely used and employed by the Netherlands Pharmacovigilance Centre and the World Health Organization, respectively [@B15], [@B16]. All of these algorithms were used to calculate signal scores to assess whether a drug was significantly associated with an adverse event or not from a two-by-two frequency table of counts. However, these calculations or algorithms, so-called disproportionality analyses or measures, differ from one another in that the ROR is frequentist (non-Bayesian), whereas the IC is Bayesian. For the ROR, a signal is detected if the lower limit of the 95% two-sided confidence interval (95% CI) is \>1 [@B15]. For the IC, a signal is detected if the IC025 metric, the lower limit of the 95% CI of the IC, is \> 0 [@B16]. In the current study, these two methods were used for signal detection, and the adverse events were considered to be drug-associated if the two indices met the criteria indicated above. Data management and analyses were performed using Visual Mining Studio software (version 8.1; Mathematical Systems, Inc. Tokyo, Japan).

Prescription sequence symmetry analysis (PSSA)
----------------------------------------------

### Data source

A large organized database of prescriptions constructed by a database vendor (Japan Medical Information Research Institute, Inc. Japan \[JMIRI\]) was used in the study. The JMIRI prescription database consists of prescriptions collected from approximately 700 pharmacies in Japan. The database includes approximately 92,700,000 prescriptions for approximately 10,300,000 patients from January 2006 to May 2014. For the PSSA, we identified cases extracted from this database for whom benzodiazepine anxiolytic drugs (Table [1](#T1){ref-type="table"}) and anti-dementia drugs (donepezil, galantamine, rivastigmine, and memantine) were prescribed at least once during the study period. The data included encrypted personal identifiers: month/year of birth and gender of the patient, drug name, unique drug code and generic name, and prescribing date. Data on drugs dispensed in hospitals were not included. This study was approved by the Ethics Committee of Kindai University School of Pharmacy.

Study design
------------

The PSSA was performed to test the hypothesis that benzodiazepines increase the risk of dementia. The PSSA method has been described in detail in several published studies investigating the associations between the use of certain target drugs and potential adverse events [@B19], [@B20]. Briefly, the PSSA evaluates asymmetry in the distribution of an incident event (e.g., prescription of another drug) before and after the initiation of a specific treatment. Asymmetry may indicate an association between the specific treatment of interest and the event. PSSA is based on a situation in which drug A is suspected of causing an adverse event that itself is treated by drug B [@B19]. In this study, anti-dementia drugs were used as markers of dementia caused by benzodiazepines, and the association between benzodiazepines and anti-dementia drug uses was analyzed.

The ratio of the numbers of patients with a prescription for anti-dementia drugs after versus before the initiation of benzodiazepines was defined as the crude sequence ratio (SR). A SR \> 1 indicated an increased risk of benzodiazepine-induced dementia. The SR is sensitive to prescribing trends over time. Therefore, the SRs were adjusted for temporal trends in benzodiazepines and anti-dementia drugs using the method proposed by Halls [@B19]. The probability that benzodiazepines were prescribed first, in the absence of any causal relationship, can be estimated by the so-called null-effect SR [@B19]. The null-effect SR yielded by the proposed model may be interpreted as a reference value for the SR. Therefore, the null-effect SR is the expected SR in the absence of any causal association, after taking the incidence trends into account. By dividing the crude SR by the null-effect SR, an adjusted SR (ASR) corrected for temporal trends is obtained. A slightly modified model was used to account for the limited time interval allowed between the benzodiazepine prescription and treatment of dementia [@B20]. The major advantage of the SR is that it is robust for confounders that are stable over time. Significant confounding factors including age, gender, and frequency of visits did not cause an asymmetrical distribution of benzodiazepines and anti-dementia drugs [@B20].

Data analysis
-------------

PSSA was undertaken to identify the new use of anti-dementia drugs, which served as a marker of benzodiazepine-induced dementia. All incident users of benzodiazepines and anti-dementia drugs were identified from January 2006 to May 2014. In this study, patients included in the database were followed up until May 2014, and therefore different patients had different follow-up periods. Incidence was defined as the first prescription of target drugs. To exclude prevalent users of target drugs, the analysis was restricted to users who presented their first prescription on July 2006 or later, that is, after a run-in period of 6 months. To ensure that our analysis was restricted to incident users, we also performed a waiting time distribution analysis [@B21]. An identical run-in period was also applied to patients enrolled in the cohort after July 2006 to exclude prevalent users of the target drugs. The analysis was based on the principle that by observing the first occurrence of a prescription within a specific time window, prevalent users of the drug will cluster at the beginning of the observation period when the prescription is repeated within a short time period. In contrast, incident users will be distributed evenly throughout the observation period. Incident users were identified by excluding those patients who had received their first prescription for the target drugs prior to June 2006. All patients were identified who initiated new treatments with both benzodiazepines and anti-dementia drugs within 3-, 6-, 12-, 24-, 36- and 48-month periods. Patients who had received their first prescriptions for benzodiazepines and anti-dementia drugs on the same date were not included in the determination of the SR.

Results are expressed as the means ± standard deviation (SD) for quantitative data and as frequencies (percentage) for categorical data. The 95% CIs for the ASRs were calculated using a method for exact CIs for binomial distributions [@B22].

Additional analysis
-------------------

The additional PSSA was performed in order to address the problem about confounding by indication and reverse causation bias. If indication and reverse causation bias is responsible for the association between benzodiazepine use and dementia, the association for recent users should be stronger than that for past users [@B23]. Therefore, patients who initiated a new treatment with benzodiazepines and anti-dementia drugs within 12- and 24-month periods were excluded from the analysis to minimize the effect of this confounding.

Results
=======

FAERS database analyses
-----------------------

A total of 1,971,750 drug-reaction pairs for dementia were found in the FAERS database. The statistical results from the FAERS database analyses are presented in Table [2](#T2){ref-type="table"}. The signal scores suggested that benzodiazepines were as**s**ociated with dementia (ROR: 1.63, 95% CI: 1.61-1.64; IC: 0.66, 95% CI: 0.65-0.67). In addition, classes of short-, medium-, long-, and ultra-long-acting benzodiazepines were also associated with dementia. The ROR and IC values increased with the duration of benzodiazepine action (Figure [1](#F1){ref-type="fig"}A). In the analyses of individual benzodiazepines, significant associations with dementia were found for etizolam, clotiazepam, lorazepam, alprazolam, bromazepam, diazepam, cloxazolam, chlordiazepoxide, medazepam, clorazepate, loflazepate, oxazolam, and prazepam.

Canada Vigilance Adverse Reaction Online Database
-------------------------------------------------

A total of 141,451 drug-reaction pairs for dementia were found in the Canada Vigilance Adverse Reaction Online Database. The statistical results from the analyses using this database are presented in Table [3](#T3){ref-type="table"}. The signal scores suggested that a class of benzodiazepines is associated with dementia (ROR: 1.88, 95% CI: 1.83-1.94; IC: 0.85, 95% CI: 0.80-0.89). In addition, medium- and long-acting benzodiazepines were also associated with dementia. The ROR and IC values of long-acting benzodiazepines were higher than those of medium-acting benzodiazepines (Figure [1](#F1){ref-type="fig"}B). In the analyses of individual benzodiazepines, significant associations with dementia were found for lorazepam, bromazepam, diazepam, chlordiazepoxide, and clorazepate.

PSSA
----

The characteristics of the study population of the PSSA are summarized in Table [4](#T4){ref-type="table"}. The number of prescriptions including those for benzodiazepines during the study period was 9,332,070. Of the 577,099 benzodiazepine users, 145,496 incident users were identified. The mean age of the incident users was 59.5 ± 18.7 years.

The associations between benzodiazepine and anti-dementia drug use are shown in Table [5](#T5){ref-type="table"}. Of the 145,496 incident users of benzodiazepines, 3,384 were also identified as incident users of anti-dementia drugs, before or after the initiation of the benzodiazepines. A significant association between benzodiazepine and anti-dementia drug use was found, with ASRs of 1.24 (1.05-1.45), 1.20 (1.06-1.37), 1.23 (1.11-1.37), 1.34 (1.23-1.47), 1.41 (1.29-1.53), and 1.44 (1.33-1.56) at intervals of 3, 6, 12, 24, 36, and 48 months, respectively. Interval-related change in the ASRs of benzodiazepines and individual classes of benzodiazepines are presented in Figure [2](#F2){ref-type="fig"}. The ASRs of benzodiazepines increased with the interval duration. The ASRs of long- and ultra-long-acting benzodiazepines were higher than those of short- and medium-acting benzodiazepines for the relatively short intervals. However, at the 48-month interval, remarkable differences were not observed among the individual classes of benzodiazepines, and all classes were associated with dementia.

A significant association between benzodiazepine and anti-dementia drug use was also found in the additional PSSA (Table [6A](#T6A){ref-type="table"}, Table [6B](#T6B){ref-type="table"}). Exclusion of the patients who initiated a new treatment with benzodiazepines and anti-dementia drugs within 12- and 24-month periods did not affect the risk of dementia induced by benzodiazepines.

A summary of the signals detected for benzodiazepine-associated dementia is presented in Table [7](#T7){ref-type="table"}.

Discussion
==========

This study suggested that benzodiazepine anxiolytic drug use is associated with the development of dementia. In the analyses of short-, medium-, long-, and ultra-long-acting benzodiazepines, all classes of benzodiazepines are associated with an increased risk of dementia. In the analysis of the FAERS database, the ROR and IC values increased with the duration of benzodiazepine action. In the Canada Vigilance Adverse Reaction Online Database, the ROR and IC values of long-acting benzodiazepines were higher than those of medium-acting benzodiazepines. In the PSSA, ASRs of ultra-long- and long-acting benzodiazepines were higher than those of short- and medium-acting benzodiazepines at relatively short intervals. Given these considerations, it is reasonable to assume that the strength of the association between benzodiazepine use and dementia was stronger for long-acting than for short-acting benzodiazepines. This finding is consistent with a previously reported case-control study investigating the relationship between the risk of Alzheimer\'s disease and exposure to benzodiazepines [@B24]. In addition, the ASR of benzodiazepines increased with the interval duration, suggesting that long-term use of benzodiazepines might be associated with an increased risk of dementia. Although we did not directly investigate the relationships between the benzodiazepine cumulative dose and treatment duration and the risk of dementia, our findings obtained from the PSSA supported the hypothesis that long-term use of benzodiazepines was associated with an increased risk of dementia.

The association between benzodiazepine use and dementia might be an early marker of a condition associated with an increased risk of dementia rather than a cause of the dementia itself. Some studies suggested that the frequency of symptoms is highly correlated with an increase in benzodiazepine prescriptions during the years preceding a diagnosis of dementia [@B12], [@B25], [@B26]. Therefore, the observed association between benzodiazepine use and dementia may be due to confounding by indication and reverse causation. If reverse causation is responsible for the association between benzodiazepine use and dementia, the association for recent users should be stronger than that for past users. Imfeld et al. reported increased risks of developing Alzheimer\'s disease and vascular dementia in those who started benzodiazepines \<1 year before diagnosis, but not for those who started them 2-4 years before diagnosis [@B23]. On the other hand, Zhong et al. recently reported in a meta-analysis that long-term benzodiazepine users have an increased risk of dementia compared with never users [@B7], attenuating the likelihood that reverse causation plays a role. In our study, the risk of dementia for benzodiazepines increased with the interval duration in the PSSA. Furthermore, the additional PSSA, in which patients who initiated a new treatment with benzodiazepines close to the prescription of anti-dementia drugs were excluded from the analysis, also demonstrated significant associations of benzodiazepine use with dementia risk. These findings suggested that confounding by indication and reverse causation bias may not have a serious impact on the study. However, from the perspective of drug action duration, ultra-long- and long-acting benzodiazepines showed declining risks with an increasing interval duration, suggesting that reverse causation might play a role in some cases during the early phase of treatment. Although this finding might support the likelihood of reverse causation having an influence, significantly increased risks were observed for all classes of benzodiazepines at the 48-month interval. Therefore, it is reasonable to consider that long-term use of benzodiazepines is associated with an increased risk of dementia.

Analysis of spontaneous reporting databases is a useful method for identifying risk signals; however, there are several potential limitations that should be taken into account when interpreting the results. First, there is no certainty that the reported event was actually due to the drug. Second, not every adverse event or medication error associated with a drug product gets reported to the regulating authorities. Third, no individual database or algorithm has been found to be sufficient for signal detection. Therefore, a different methodology, PSSA of the JMIRI prescription database, was used to confirm the findings from spontaneous reporting databases. Of course, there are several potential limitations associated with such an analysis based on a database of prescriptions collected from pharmacies. First, anti-Alzheimer\'s disease drugs were used as surrogate markers for dementia. Therefore, to be precise, the association between benzodiazepine use and Alzheimer\'s disease was evaluated in the analysis of the JMIRI database. In addition, individual cases were not reviewed, and other causes were not considered; therefore, some patients may not in fact have had dementia. Conversely, the PSSA is similar to the case-crossover design, in which exposures during a fixed period before the case date (date when the target outcome occurred) are compared with certain prior dates in the same individual [@B27]. These within-subject comparisons can thus be fully controlled for potential confounding due to between-subject differences and time-invariant characteristics, e.g., age, gender, genetic factors, mental health status, and other unknown confounding factors. PSSA has been employed in a number of previous studies investigating the associations between use of certain target drugs and potential adverse events [@B13], [@B14], [@B19], [@B20], [@B28], and the validity of the PSSA has been confirmed by previous studies [@B29], [@B30].

Although a plausible pharmacological mechanism for dementia is unknown, several theories have been reported. Benzodiazepines have deleterious effects on memory, and benzodiazepine use induces both non-amnestic and amnestic mild cognitive impairment [@B31], [@B32]. This effect may precipitate dementia progression [@B33], [@B34]. Long-term administration of benzodiazepines down-regulates the levels of their binding receptors [@B35], resulting in a cognitive decline [@B36]. We found that benzodiazepine use, particularly long-acting drugs, might be associated with increased risks of dementia. If these observed associations are causal, benzodiazepines should be used as briefly as possible to reduce possible adverse reactions.

Conclusions
===========

The results of a multi-methodological approach, using different methods, algorithms, and databases, suggest that benzodiazepine use, especially long-term use and long-acting drugs, is associated with an increased risk of dementia. Individuals prescribed benzodiazepines should be considered to have an increased risk of dementia. Although the biological mechanism for this phenomenon remains unknown, the risk of dementia associated with benzodiazepine use is a very important finding in clinical practice. Patients using benzodiazepines should be closely monitored for the development of dementia in clinical practice, and further studies are needed to confirm our findings and elucidate the mechanisms underlying benzodiazepine-induced dementia.

We thank the Japan Medical Information Research Institute, Inc. for providing the database of prescriptions.
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###### 

Benzodiazepine anxiolytic drugs.

  ------------------- ---------------
  Short-acting        Etizolam
  Clotiazepam         
  Flutazolam          
  Medium-acting       Lorazepam
  Alprazolam          
  Fludiazepam         
  Bromazepam          
  Nimetazepam         
  Long-acting         Diazepam
  Cloxazolam          
  Chlordiazepoxide    
  Medazepam           
  Clorazepate         
  Ultra-long-acting   Flutoprazepam
  Loflazepate         
  Mexazolam           
  Oxazolam            
  Prazepam            
  ------------------- ---------------

###### 

The association between individual benzodiazepine use and dementia based on the FAERS database.

                      Cases    Non-cases   ROR    95% CI       IC      95% CI
  ------------------- -------- ----------- ------ ------------ ------- ------------
  Benzodiazepines     50,302   1,001,070   1.63   1.61-1.64    0.66    0.65-0.67
  Short-acting        800      18,637      1.38   1.28-1.48    0.44    0.34-0.55
  Etizolam            691      16,019      1.38   1.28-1.49    0.45    0.34-0.56
  Clotiazepam         107      2,597       1.32   1.09-1.60    0.38    0.10-0.67
  Flutazolam          2        21          3.05   0.72-13.01   0.80    -0.97-2.56
                                                                       
  Medium-acting       35,772   739,016     1.56   1.54-1.58    0.61    0.59-0.62
  Lorazepam           16,245   327959      1.59   1.57-1.62    0.64    0.62-0.66
  Alprazolam          18,075   384,519     1.51   1.49-1.53    0.57    0.55-0.59
  Fludiazepam         3        279         0.34   0.11-1.07    -1.26   -2.71-0.20
  Bromazepam          1,444    26,161      1.77   1.68-1.87    0.79    0.71-0.87
  Nimetazepam         5        98          1.63   0.67-4.02    0.53    -0.68-1.74
                                                                       
  Long-acting         13,186   233,750     1.81   1.78-1.85    0.82    0.79-0.84
  Diazepam            11,267   195,417     1.85   1.82-1.89    0.85    0.82-0.88
  Cloxazolam          200      3,084       2.08   1.80-2.40    1.00    0.79-1.21
  Chlordiazepoxide    740      17,880      1.33   1.23-1.43    0.39    0.28-0.50
  Medazepam           15       220         2.18   1.29-3.69    0.97    0.23-1.72
  Clorazepate         964      17,149      1.80   1.69-1.92    0.81    0.72-0.91
                                                                       
  Ultra-long-acting   544      9,667       1.80   1.65-1.97    0.81    0.69-0.94
  Flutoprazepam       6        161         1.19   0.53-2.70    0.20    -0.91-1.32
  Loflazepate         185      3,483       1.70   1.47-1.97    0.73    0.51-0.95
  Mexazolam           7        182         1.23   0.58-2.62    0.24    -0.80-1.29
  Oxazolam            18       294         1.96   1.22-3.16    0.86    0.18-1.54

Cases: number of reports of dementia

Non-cases: all reports of adverse drug reactions other than dementia

ROR: reporting odds ratio

IC: information component

CI: confidence interval

###### 

The association between individual benzodiazepine use and dementia based on the Canada Vigilance Adverse Reaction Online Database

                      Cases   Non-cases   ROR    95% CI      IC      95% CI
  ------------------- ------- ----------- ------ ----------- ------- ------------
  Benzodiazepines     4,877   72,164      1.88   1.83-1.94   0.85    0.80-0.89
  Short-acting        \-      \-          \-     \-          \-      \-
                                                                     
  Medium-acting       3,317   54979       1.67   1.61-1.73   0.69    0.64-0.74
  Lorazepam           2,818   41,481      1.88   1.81-1.95   0.85    0.80-0.91
  Alprazolam          404     11,810      0.94   0.85-1.04   -0.09   -0.24-0.06
  Bromazepam          95      1,688       1.54   1.26-1.90   0.59    0.29-0.89
                                                                     
  Long-acting         1,560   17,185      2.51   2.38-2.64   1.24    1.16-1.32
  Diazepam            1,268   14,463      2.42   2.28-2.56   1.19    1.11-1.28
  Chlordiazepoxide    256     2,360       2.98   2.62-3.39   1.47    1.28-1.65
  Medazepam           0       10          0.00   \-          -0.47   -3.49-2.54
  Clorazepate         36      352         2.80   1.99-3.95   1.33    0.84-1.83
                                                                     
  Ultra-long-acting   \-      \-          \-     \-          \-      \-

Cases: number of reports of dementia

Non-cases: all reports of adverse drug reactions other than dementia

ROR: reporting odds ratio

IC: information component

CI: confidence interval

###### 

Characteristics of the study population in the prescription sequence symmetry analysis

                                    Total              Male            Female
  --------------------------------- --------------- -- --------------- ---------------
  Benzodiazepine prescriptions, n   9,332,070                          
  Users                             577,099                            
  Incident users, n                 145,496            49,972 (34.3)   95,524 (65.7)
  Age, years, n (%)                                                    
  \<20                              3,202 (2.2)        1,350 (2.7)     1,852 (1.9)
  20-39                             22,550 (15.5)      7,607 (15.2)    14,943 (15.6)
  40-59                             37,253 (25.6)      13,327 (25.6)   23,926 (25.0)
  60-79                             63,207 (43.4)      21,706 (43.4)   41,501 (43.4)
  ≥80                               19,284 (13.3)      5,982 (13.3)    13,302 (12.0)
  Mean ± SD                         59.5 ± 18.7        58.9 ± 18.6     59.8 ± 18.7

SD: standard deviation

###### 

Prescription sequence symmetry analysis: associations of benzodiazepine use with dementia

                      Incidentusers   Concomitant use with anti-dementia drugs   Interval(months)   No. of patients prescribed anti-dementia drugs   Adjusted SR   95% CI                 
  ------------------- --------------- ------------------------------------------ ------------------ ------------------------------------------------ ------------- -------- ------ ------ --
  Benzodiazepines     145,496         3,384                                      3                  348                                              277           1.24     1.05   1.45   
  6                   539             434                                        1.20               1.06                                             1.37                                 
  12                  821             629                                        1.23               1.11                                             1.37                                 
  24                  1,233           816                                        1.34               1.23                                             1.47                                 
  36                  1,514           894                                        1.41               1.29                                             1.53                                 
  48                  1,718           935                                        1.44               1.33                                             1.56                                 
  Short-acting        107,866         2,563                                      3                  242                                              203           1.17     0.97   1.42   
  6                   399             326                                        1.18               1.02                                             1.38                                 
  12                  607             475                                        1.20               1.06                                             1.36                                 
  24                  924             617                                        1.32               1.19                                             1.46                                 
  36                  1,159           672                                        1.42               1.29                                             1.56                                 
  48                  1,310           703                                        1.44               1.32                                             1.58                                 
  Medium-acting       41,870          1,082                                      3                  106                                              105           1.00     0.75   1.32   
  6                   158             164                                        0.94               0.75                                             1.17                                 
  12                  252             231                                        1.03               0.86                                             1.24                                 
  24                  371             295                                        1.13               0.97                                             1.32                                 
  36                  457             336                                        1.15               1.00                                             1.33                                 
  48                  522             353                                        1.18               1.03                                             1.35                                 
  Long-acting         31,698          773                                        3                  83                                               52            1.57     1.09   2.26   
  6                   124             88                                         1.36               1.02                                             1.80                                 
  12                  181             127                                        1.32               1.05                                             1.67                                 
  24                  272             180                                        1.31               1.08                                             1.59                                 
  36                  340             197                                        1.39               1.16                                             1.66                                 
  48                  401             214                                        1.42               1.20                                             1.68                                 
  Ultra-long-acting   20,492          492                                        3                  64                                               35            1.80     1.17   2.80   
  6                   103             58                                         1.71               1.23                                             2.41                                 
  12                  146             90                                         1.51               1.15                                             1.99                                 
  24                  206             118                                        1.51               1.20                                             1.91                                 
  36                  242             135                                        1.44               1.16                                             1.79                                 
  48                  264             141                                        1.41               1.15                                             1.75                                 

Incident users: number of patients who received their first prescription for benzodiazepines

No. of patients prescribed anti-dementia drugs last: the number of patients prescribed anti-dementia drugs after benzodiazepine use

No. of patients prescribed anti-dementia drugs last: the number of patients prescribed anti-dementia drugs before benzodiazepine use

Adjusted SR: adjusted sequence ratio

CI: confidence interval

###### 

Additional prescription sequence symmetry analysis. Patients who initiated a new treatment with benzodiazepines and anti-dementia drugs within 12-month period were excluded from the analysis.

                    Interval(months)   No. of patients prescribed anti-dementia drugs   Adjusted SR   95% CI                 
  ----------------- ------------------ ------------------------------------------------ ------------- -------- ------ ------ --
  Benzodiazepines   24                 412                                              187           1.96     1.64   2.34   
  36                693                265                                              2.17          1.88     2.51          
  48                897                306                                              2.30          2.01     2.62          

Incident users: number of patients who received their first prescription for benzodiazepines

No. of patients prescribed anti-dementia drugs last: the number of patients prescribed anti-dementia drugs after benzodiazepine use

No. of patients prescribed anti-dementia drugs last: the number of patients prescribed anti-dementia drugs before benzodiazepine use

Adjusted SR: adjusted sequence ratio

CI: confidence interval

###### 

Additional prescription sequence symmetry analysis. Patients who initiated a new treatment with benzodiazepines and anti-dementia drugs within 24-month period were excluded from the analysis.

                    Interval(months)   No. of patients prescribed anti-dementia drugs   Adjusted SR   95% CI                 
  ----------------- ------------------ ------------------------------------------------ ------------- -------- ------ ------ --
  Benzodiazepines   36                 281                                              78            2.99     2.32   3.90   
  48                485                119                                              3.19          2.61     3.94          

Incident users: number of patients who received their first prescription for benzodiazepines

No. of patients prescribed anti-dementia drugs last: the number of patients prescribed anti-dementia drugs after benzodiazepine use

No. of patients prescribed anti-dementia drugs last: the number of patients prescribed anti-dementia drugs before benzodiazepine use

Adjusted SR: adjusted sequence ratio

CI: confidence interval

###### 

Summary of signal detection for benzodiazepine-associated dementia

                      FAERS   Canada   Prescription
  ------------------- ------- -------- --------------
  Benzodiazepines     ↑       ↑        ↑
  Short-acting        ↑       \-       ↑
  Etizolam            ↑       \-       ↑
  Clotiazepam         ↑       \-       ↑
  Flutazolam          nd      \-       nd
                                       
  Medium-acting       ↑       ↑        ↑
  Lorazepam           ↑       ↑        nd
  Alprazolam          ↑       nd       nd
  Fludiazepam         nd      \-       nd
  Bromazepam          ↑       ↑        ↑
  Nimetazepam         nd      \-       nd
                                       
  Long-acting         ↑       ↑        ↑
  Diazepam            ↑       ↑        ↑
  Cloxazolam          ↑       \-       ↑
  Chlordiazepoxide    ↑       ↑        ↑
  Medazepam           ↑       \-       nd
  Clorazepate         ↑       ↑        nd
                                       
  Ultra-long-acting   ↑       \-       ↑
  Flutoprazepam       nd      \-       nd
  Loflazepate         ↑       \-       ↑
  Mexazolam           nd      \-       nd
  Oxazolam            ↑       \-       nd
  Prazepam            ↑       \-       \-

FAERS: The US Food and Drug Administration (FDA) Adverse Event Reporting System

↑: A positive signal was detected (This means the benzodiazepine anxiolytic drug may be associated with an increased risk of dementia).

nd: A signal was not detected.
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